• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » St. Jude gets the green light for U.S. EnligHTN IV renal denervation study

St. Jude gets the green light for U.S. EnligHTN IV renal denervation study

June 5, 2013 By Sony Salzman

St. Jude gets the green light for U.S. EnligHTN IV renal denervation study

 St. Jude Medical (NYSE:STJ) this week announced that it launched its EnligHTN IV renal denervation study, the 1st U.S. trial evaluating the company’s EnligHTN system in treatment of drug-resistant high blood pressure under Investigational Device Exemption from the FDA.

St. Jude will enroll about 590 patients between the ages of 18 and 80 who have hypertension that isn’t well-managed with drugs, treating them with the EnligHTN Multi-Electrode renal denervation system.

The device applies radiofrequency energy to create tiny scars along nerves that control blood pressure. A multi-electrode catheter and newer energy generator (which wasn’t part of the EnligHTN IV trial) may cut procedure times from around 24 minutes apiece to 4 minutes, the company said.

The EnligHTN I through III trials took place in Australia, Greece, Europe and New Zealand, and the company recently presented positive 1-year results from the EnligHTN I trial at the annual EuroPCR meeting in Paris.

This month, the St. Paul, Minn.-based medical device company also began enrollment in the EnligHTN III trial,

"The EnligHTN IV study represents another important step in our commitment to advancing science, technology and clinical evidence that supports renal denervation for the millions of patients who live with uncontrolled high blood pressure," Frank Callaghan, president of St. Jude’s cardiovascular division, said in the statement.

Approximately 1 in 3 Americans has hypertension, or high blood pressure and this condition puts patients at high risk for heart attack, stroke and kidney failure, according to a company statement.

Filed Under: News Well Tagged With: Clinical Trials, Hypertension, Minnesota, Renal, stjudemedical

More recent news

  • Medtronic escapes $106.5M payment in Colibri TAVR patent suit after court overturns jury verdict
  • RadNet closes iCAD acquisition, expands AI breast‑imaging portfolio
  • Hyperfine reports first commercial sales of next-gen AI-powered Swoop
  • Stereotaxis announces $12.5M offering
  • Nuwellis ends clinical trial of its ultrafiltration tech for heart failure

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy